EP3880176A4 - Compositions pharmaceutiques à libération prolongée comprenant un agent thérapeutique pour le traitement de maladies dues à une densité osseuse réduite ou à une perte de cartilage et leurs utilisations - Google Patents

Compositions pharmaceutiques à libération prolongée comprenant un agent thérapeutique pour le traitement de maladies dues à une densité osseuse réduite ou à une perte de cartilage et leurs utilisations Download PDF

Info

Publication number
EP3880176A4
EP3880176A4 EP19884612.3A EP19884612A EP3880176A4 EP 3880176 A4 EP3880176 A4 EP 3880176A4 EP 19884612 A EP19884612 A EP 19884612A EP 3880176 A4 EP3880176 A4 EP 3880176A4
Authority
EP
European Patent Office
Prior art keywords
sustained
treatment
pharmaceutical compositions
therapeutic agent
bone density
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19884612.3A
Other languages
German (de)
English (en)
Other versions
EP3880176A1 (fr
Inventor
Keelung Hong
Hao-Wen Kao
Yi-Yu Lin
Jonathan FANG
Weiwei FANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiwan Liposome Co Ltd
TLC Biopharmaceuticals Inc
Original Assignee
Taiwan Liposome Co Ltd
TLC Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Co Ltd, TLC Biopharmaceuticals Inc filed Critical Taiwan Liposome Co Ltd
Publication of EP3880176A1 publication Critical patent/EP3880176A1/fr
Publication of EP3880176A4 publication Critical patent/EP3880176A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
EP19884612.3A 2018-11-14 2019-11-13 Compositions pharmaceutiques à libération prolongée comprenant un agent thérapeutique pour le traitement de maladies dues à une densité osseuse réduite ou à une perte de cartilage et leurs utilisations Withdrawn EP3880176A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767254P 2018-11-14 2018-11-14
PCT/US2019/061143 WO2020102323A1 (fr) 2018-11-14 2019-11-13 Compositions pharmaceutiques à libération prolongée comprenant un agent thérapeutique pour le traitement de maladies dues à une densité osseuse réduite ou à une perte de cartilage et leurs utilisations

Publications (2)

Publication Number Publication Date
EP3880176A1 EP3880176A1 (fr) 2021-09-22
EP3880176A4 true EP3880176A4 (fr) 2022-08-03

Family

ID=70730604

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19884612.3A Withdrawn EP3880176A4 (fr) 2018-11-14 2019-11-13 Compositions pharmaceutiques à libération prolongée comprenant un agent thérapeutique pour le traitement de maladies dues à une densité osseuse réduite ou à une perte de cartilage et leurs utilisations

Country Status (5)

Country Link
EP (1) EP3880176A4 (fr)
JP (1) JP7431419B2 (fr)
CN (1) CN113056259A (fr)
TW (1) TWI729562B (fr)
WO (1) WO2020102323A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101199505A (zh) * 2007-12-20 2008-06-18 沈阳药科大学 维拉帕米脂质体及其制备方法
CN102406606A (zh) * 2011-11-29 2012-04-11 海南美大制药有限公司 富马酸喹硫平脂质体固体制剂
US20130202686A1 (en) * 2010-12-27 2013-08-08 Terumo Kabushiki Kaisha Liposome composition and process for production thereof
WO2017066726A1 (fr) * 2015-10-16 2017-04-20 Merrimack Pharmaceuticals, Inc. Stabilisation de compositions pharmaceutiques de camptothécine
WO2017193139A1 (fr) * 2016-05-06 2017-11-09 The Brigham And Women's Hospital, Inc. Gels auto-assemblés binaires pour l'administration contrôlée d'agents encapsulés dans un cartilage
US9877918B2 (en) * 2011-03-25 2018-01-30 Terumo Kabushiki Kaisha Long-lasting controlled-release liposome composition and method for producing same
WO2020023445A1 (fr) * 2018-07-24 2020-01-30 Taiwan Liposome Co., Ltd. Compositions pharmaceutiques à libération prolongée comprenant un agent thérapeutique permettant le traitement de la démence, et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
AU2006302797B2 (en) 2005-03-02 2012-02-02 Merck Canada Inc. Composition for inhibition of cathepsin K
CA2834968C (fr) * 2011-01-05 2018-01-09 Livon Laboratories Procedes de fabrication de liposomes, compositions a base de liposomes preparees en utilisant les procedes, et procedes d'utilisation associes
EP2537532A1 (fr) 2011-06-22 2012-12-26 J. Stefan Institute Composés capables de se lier à une cathepsine, liés à un nanodispositif et leur utilisation thérapeutique et diagnostique
EP2734500A4 (fr) * 2011-07-20 2015-04-08 Gen Hospital Corp Inhibiteurs sélectifs de l'histone désacétylase 6 pour le traitement d'une maladie osseuse
SI2854769T1 (sl) * 2012-07-05 2023-09-29 Taiwan Liposome Company, Ltd. Postopki za zdravljenje artritisa
WO2014121211A2 (fr) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Chargement à distance de médicaments médiocrement solubles dans l'eau dans des liposomes

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101199505A (zh) * 2007-12-20 2008-06-18 沈阳药科大学 维拉帕米脂质体及其制备方法
US20130202686A1 (en) * 2010-12-27 2013-08-08 Terumo Kabushiki Kaisha Liposome composition and process for production thereof
US9877918B2 (en) * 2011-03-25 2018-01-30 Terumo Kabushiki Kaisha Long-lasting controlled-release liposome composition and method for producing same
CN102406606A (zh) * 2011-11-29 2012-04-11 海南美大制药有限公司 富马酸喹硫平脂质体固体制剂
WO2017066726A1 (fr) * 2015-10-16 2017-04-20 Merrimack Pharmaceuticals, Inc. Stabilisation de compositions pharmaceutiques de camptothécine
WO2017193139A1 (fr) * 2016-05-06 2017-11-09 The Brigham And Women's Hospital, Inc. Gels auto-assemblés binaires pour l'administration contrôlée d'agents encapsulés dans un cartilage
WO2020023445A1 (fr) * 2018-07-24 2020-01-30 Taiwan Liposome Co., Ltd. Compositions pharmaceutiques à libération prolongée comprenant un agent thérapeutique permettant le traitement de la démence, et leurs utilisations

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEN J ET AL: "Preparation and pharmacokinetic investigation of propranolol-loaded elastic liposomes composed of DP-PC and SPC", CHINESE PHARMACEUTICAL JOURNAL, ZHONGGUO YAOXUEHUI ZHUBAN CHUBAN. ZHONGGUO-YAOXUE-ZAZHI BIANJI WEIYUANHUI, CN, vol. 48, no. 20, 22 October 2013 (2013-10-22), pages 1761 - 1765, XP009534476, ISSN: 1001-2494 *
EL-MEZAYEN NESRINE S ET AL: "Hepatic stellate cell-targeted imatinib nanomedicineversusconventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 266, 28 September 2017 (2017-09-28), pages 226 - 237, XP085292753, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2017.09.035 *
KIM HYEONGSEOK ET AL: "Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 678, no. 1, 23 November 2011 (2011-11-23), pages 55 - 60, XP028891080, ISSN: 0014-2999, DOI: 10.1016/J.EJPHAR.2011.12.017 *
SATO TSUYOSHI ET AL: "Donepezil prevents RANK-induced bone loss via inhibition of osteoclast differentiation by downregulating acetylcholinesterase", HELIYON, vol. 1, no. 1, 1 September 2015 (2015-09-01), GB, pages e00013, XP055935707, ISSN: 2405-8440, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939821/pdf/main.pdf> DOI: 10.1016/j.heliyon.2015.e00013 *
See also references of WO2020102323A1 *
TAKAMATSU AKIRA ET AL: "Verapamil Protects against Cartilage Degradation in Osteoarthritis by Inhibiting Wnt/[beta]-Catenin Signaling", PLOS ONE, vol. 9, no. 3, 21 January 2014 (2014-01-21), pages e92699, XP055935688, DOI: 10.1371/journal.pone.0092699 *
TORU HIRAGA ET AL: "Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals", INTERNATIONAL JOURNAL OF CANCER, vol. 124, no. 1, 1 January 2009 (2009-01-01), US, pages 215 - 222, XP055292283, ISSN: 0020-7136, DOI: 10.1002/ijc.23903 *
ZHANG XINGGUANG ET AL: "Propranolol Prevents Osteoporosis and up-regulates Leptin in Ovariectomized Rats", IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH : IJPR, 1 January 2013 (2013-01-01), Iran, pages 557 - 562, XP055935721, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813260/pdf/ijpr-12-557.pdf> [retrieved on 20220627] *

Also Published As

Publication number Publication date
TW202031247A (zh) 2020-09-01
TWI729562B (zh) 2021-06-01
EP3880176A1 (fr) 2021-09-22
WO2020102323A1 (fr) 2020-05-22
CN113056259A (zh) 2021-06-29
JP2023510658A (ja) 2023-03-15
JP7431419B2 (ja) 2024-02-15

Similar Documents

Publication Publication Date Title
EP3830259A4 (fr) Complexes de ciblage musculaire et leurs utilisations pour le traitement de la dystrophie musculaire facio-scapulo-humérale
EP3810601A4 (fr) Composés pyrimidine et compositions pharmaceutiques pour la prévention ou le traitement de cancers les comprenant
MA51739A (fr) Compositions pharmaceutiques pour le traitement de la fibrose kystique
EP3463304A4 (fr) Compositions comprenant du cannabidiol et de l&#39;acide hyaluronique pour le traitement de maladies inflammatoires des articulations
EP3639833A4 (fr) Agent pour la prévention ou le traitement de maladies liées à la graisse et/ou de l&#39;inflammation
MA53665B1 (fr) Agonistes du récepteur farnésoïde x et leurs utilisations
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
EP3498279A4 (fr) Composition pharmaceutique comprenant comme principes actifs de l&#39;amodiaquine et un médicament anti-diabète, destinée à la prévention ou le traitement du diabète
EP3737376A4 (fr) Inhibiteurs sélectifs d&#39;histone déacétylase pour le traitement d&#39;une maladie humaine
EP3826615A4 (fr) Compositions pharmaceutiques à libération prolongée comprenant un agent thérapeutique permettant le traitement de la démence, et leurs utilisations
EP3841086A4 (fr) Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément
EP3876967A4 (fr) Microbiote thérapeutique pour le traitement et/ou la prévention d&#39;une dysbiose
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
EP3791869A4 (fr) Composition pharmaceutique de prévention ou de traitement de maladies neurodégénératives comprenant l&#39;agent d&#39;acétylation cox2 comme ingrédient actif
EP3877383A4 (fr) Composés et compositions pour le traitement de maladies respiratoires
EP3362096A4 (fr) Composition de traitement ophtalmique et véhicule pour l&#39;administration de substances pharmaceutiques ou d&#39;agents thérapeutiques
MA54522A (fr) Composition pharmaceutique pour le traitement de l&#39;hypertension artérielle pulmonaire
EP3804736A4 (fr) Composition pharmaceutique comprenant des cellules souches mésenchymateuses en tant qu&#39;ingrédient efficace pour la prévention ou le traitement d&#39;une maladie inflammatoire
EP3804739A4 (fr) Composition comprenant un extrait d&#39;aster sphathulifolius maxim pour la prévention, l&#39;amélioration ou le traitement des maladies musculaires ou pour l&#39;amélioration des fonctions musculaires
MA55872A (fr) Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires
EP3829539A4 (fr) Compositions à libération prolongée comprenant un agent thérapeutique de traitement de la dépression ou de l&#39;anxiété et leurs utilisations
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EP3880709A4 (fr) Schéma posologique d&#39;un anticorps anti-lag3 et polythérapie avec un anticorps anti-pd-1 pour le traitement du cancer
EP3827831A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de la stéatohépatite non alcoolique
EP3785718A4 (fr) Composition pharmaceutique pour la prévention ou le traitement d&#39;une maladie infectieuse de flavivirus

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210512

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0009000000

Ipc: A61K0009127000

A4 Supplementary search report drawn up and despatched

Effective date: 20220706

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/26 20060101ALI20220630BHEP

Ipc: A61K 47/02 20060101ALI20220630BHEP

Ipc: A61P 35/00 20060101ALI20220630BHEP

Ipc: A61K 31/496 20060101ALI20220630BHEP

Ipc: A61K 9/00 20060101ALI20220630BHEP

Ipc: A61K 31/495 20060101ALI20220630BHEP

Ipc: A61K 9/127 20060101AFI20220630BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250603